Highlights Abivax

Equities

ABVX

FR0012333284

Market Closed - Euronext Paris Other stock markets 11:35:25 2024-04-29 am EDT			5-day change	1st Jan Change
14.82 ^EUR	0.00%		+2.92%	+50.92%

Apr. 29	Abivax: share price rises as two analysts express optimism	CF
Apr. 29	Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn?s Disease	Feb. 02	CI
Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis	Jan. 24	CI
Abivax: share price rises after strategic update	Jan. 22	CF
Abivax Raises $235.8 Million via Nasdaq IPO	23-10-24	MT
Abivax Closes Nasdaq IPO With $235.8 Million in Gross Proceeds	23-10-24	MT
Abivax Prices Nasdaq IPO; Trading Resumes in Paris	23-10-20	MT
Abivax: Nasdaq IPO price at bottom of range	23-10-20	CF
Abivax Shares Temporarily Suspended from Trading on Euronext Paris	23-10-20	MT
Abivax Sets Price Range for Public Offering of American Depositary Shares in US	23-10-19	MT
Abivax Files for Public Offering of American Depositary Shares in US	23-10-02	MT
ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.	23-09-29	CI
ABIVAX Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD	22-12-20	CI
ABIVAX Société Anonyme completed the acquisition of Prosynergia.	22-12-11	CI
Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis	22-10-11	CI
ABIVAX Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-15	CI
Abivax SA Announces Phase 2B Study Results of Obefazimod in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology	22-09-06	CI
Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval	22-08-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Abivax

Equities

ABVX

FR0012333284

Highlights

Filters